<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438256</url>
  </required_header>
  <id_info>
    <org_study_id>06-248</org_study_id>
    <nct_id>NCT00438256</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer</brief_title>
  <official_title>Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A standard treatment for pancreatic cancer is radiation therapy plus chemotherapy after
      surgery. Radiation therapy and chemotherapy are commonly given for up to six weeks. Previous
      research has suggested that giving the radiation and chemotherapy for a shorter amount of
      time (accelerated schedule) before surgery may be better tolerated. In this research study,
      different schedules of proton radiation therapy will be used. Each schedule will give about
      the same total dose of radiation. However, the total dose will be spread out over different
      time periods and different numbers of sessions. The purpose is to find the shortest schedule
      of radiation therapy that can be given without unacceptable side effects. Proton beam
      radiation is being used because of its unique ability to deposit its energy directly in the
      tumor, resulting in less radiation to normal tissue. A new type of PET scan is also being
      studied to see if it can help predict the response to pre-surgery treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Not everyone who participates in this research study will receive the same schedule of
           radiation therapy. The schedule of radiation therapy will depend on the number of
           participants enrolled on the study and how well they have tolerated their radiation
           schedule. All patients will receive proton beam therapy.

        -  Here are the proposed schedules of radiation therapy. If at any point too many subjects
           experience too many unacceptable side effects, no subject will be enrolled to the next
           level. Dose Level 1: 10 radiation sessions given Monday-Friday for two weeks. Dose Level
           2: 5 radiation sessions given Monday, Wednesday and Friday in Week 1 and Tuesday and
           Thursday in Week 2. Dose Level 3: 5 radiation sessions given Monday, Tuesday, Thursday
           and Friday in Week 1 and Monday in Week 2. Dose Level 4: 5 Radiation sessions given
           Monday through Friday in Week 1.

        -  In Dose Levels 2, 3 and 4, there are fewer radiation sessions, but the radiation dose
           given at each session is slightly higher than the dose given in each of the 10 sessions
           of Dose Level 1.

        -  Capecitabine will be given orally (pill form) starting on the first day of radiation
           therapy and will be taken for the two weeks that the participant receives radiation
           therapy.

        -  On days 1, 8 and 15 of each study cycle, the participant will be seen at the clinic for:
           physical examination, questions about side effects; and routine blood tests.

        -  After the last day of study treatment there will be up to a six-week rest period before
           surgery is performed.

        -  About three to six weeks after the participant has finished study treatment, the
           following procedures will be done: CT or MRI, physical examination; questions about side
           effects and blood tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities in the 5 Radiation Sessions in One Week Arm</measure>
    <time_frame>3 Weeks</time_frame>
    <description>The number of participants that experienced a dose limiting toxicity in the arm where radiation was administered over 5 consecutive for a total dose of 25 Gray Equivalents (GyE) (Group 4). Participants were monitored for potential Dose Limiting Toxicities (DLT) for three weeks after the start of radiation. DLTs included:
Any grade 3 non-hematologic or hematologic toxicity requiring a greater than 7 day interruption in therapy (excluding alopecia and nausea/vomiting not controlled by optimal supportive care or
Any grade 4 non-hematologic toxicity or
Any grade 4 neutropenia or thrombocytopenia as defined by Common Terminology Criteria for Adverse Events (CTCAE v3.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 or Greater Toxicity in Phase II</measure>
    <time_frame>30 days after the end of treatment, up to approximately 6 months total</time_frame>
    <description>Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3). The regimen was considered to be tolerated if less than 20% of participants experienced a grade 3 or greater toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Pathological Complete Response</measure>
    <time_frame>at the time of surgery (28-42 days after start of treatment)</time_frame>
    <description>All patients that received surgery underwent a full pathological review of their pancreaticoduodenectomy specimen according to the American Joint Committee on Cancer (AJCC) Staging Classification, 6th. Initial gross evaluation and identification of resection margins was performed jointly by the surgeon and the pathologist. Pathological complete response will be defined as the absence of any viable tumor cells within the pathologic specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival</measure>
    <time_frame>from the start of treatment until death or progression, median duration of 10.4 months</time_frame>
    <description>The median amount of time from the start of treatment until death or disease progression, whichever occurs first.
Progressive Disease (PD): A 20% or greater increase in the sum of Longest Diameter (LD) of all target lesions, taking as reference the smallest sum LD recorded since baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Morbidity</measure>
    <time_frame>30 days post surgery (surgery was 28-42 days after the start of treatment)</time_frame>
    <description>Number of participants with pancreatic or any other anastomotic leakage within 30 days of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-Day Post Operative Mortality</measure>
    <time_frame>30 days after the time of surgery (Surgery is 28-42 days after start of treatment)</time_frame>
    <description>The number of participants that died within 30 days of undergoing a pancreaticoduodenectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Related Serious Adverse Events</measure>
    <time_frame>From the start of treatment until 30 days after the end of treatment, up to approximately 5 months</time_frame>
    <description>The number of participants that had treatment related serious adverse events. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3). Adverse events were considered to be serious adverse events if they were grade 3 or greater and were considered to be possibly, probably, or definitely related to treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Radiation Sessions over 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Radiation sessions: 3 in week 1 and 2 in week 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Radiation sessions: 4 in week 1 and 1 in week 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Radiation Sessions in one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Proton Beam Radiation</intervention_name>
    <description>Given over different schedules and duration</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given orally starting on day one of radiation therapy for 2 weeks</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic of histologic proof of pancreatic ductal carcinoma

          -  No evidence of metastatic disease

          -  18 years of age or older

          -  ECOG Performance Status of 0 or 1 - Lab values as outlined in the protocol

        Exclusion Criteria:

          -  Tumors in the body or tail of the pancreas

          -  Hepatic or peritoneal metastases detected by imaging or laparoscopy prior to
             chemoradiation

          -  Serious concomitant systemic disorders incompatible with the study, such as
             significant cardiac or pulmonary morbidity, ongoing infection as manifested by fever

          -  Pregnant or lactating women

          -  Life expectancy of &lt; 3 months

          -  Serious, uncontrolled, concurrent infection (s)

          -  Prior chemotherapy or radiation for treatment of the patient's pancreatic tumor

          -  Clinically significant cardiac disease or myocardial infarction within the last 12
             months

          -  Other serious uncontrolled medical condition that the investigator feels might
             compromise study participation

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome

          -  Known, existing uncontrolled coagulopathy

          -  Any prior fluoropyrimidine therapy

          -  Prior unanticipated severe reaction to fluoropyrimidine therapy, or known
             hypersensitivity to a 5-fluorouracil or known DPD deficiency

          -  Participation in any investigational drug study within 4 weeks preceding the start of
             the study

          -  History of uncontrolled seizures, central nervous system disorders or psychiatric
             disability

          -  Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,
             without complete recovery

          -  Patients on cimetidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <results_first_submitted>October 11, 2018</results_first_submitted>
  <results_first_submitted_qc>December 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2019</results_first_posted>
  <last_update_submitted>December 31, 2018</last_update_submitted>
  <last_update_submitted_qc>December 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Theodore Sunki Hong</investigator_full_name>
    <investigator_title>Attending Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>accelerated short course</keyword>
  <keyword>proton beam radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 18, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT00438256/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Proton Beam Radiation/ Capecitabine Dose Level 1</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over 10 Radiation Sessions over 2 weeks
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Proton Beam Radiation/ Capecitabine Dose Level 2</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation sessions: 3 in week 1 and 2 in week 2
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Proton Beam Radiation/ Capecitabine Dose Level 3</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation sessions: 4 in week 1 and 1 in week 2
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
        <group group_id="P4">
          <title>Proton Beam Radiation/ Capecitabine Dose Level 4</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation Sessions in one week
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Surgical Resection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible for Resection</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded final Diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Phase 1 radiation schedule escalation arms were combined with the phase II dose arm to highlight overall trends of the regimen</population>
      <group_list>
        <group group_id="B1">
          <title>Proton Beam Radiation/ Capecitabine</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over different schedules and duration
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="49" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CA19-9 level at baseline</title>
          <description>Carbohydrate antigen (CA) 19-9 is an antigen released by pancreatic cancer cells.</description>
          <units>units per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136.5" lower_limit="1" upper_limit="15151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor size on CT</title>
          <units>Centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" lower_limit="1.1" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicities in the 5 Radiation Sessions in One Week Arm</title>
        <description>The number of participants that experienced a dose limiting toxicity in the arm where radiation was administered over 5 consecutive for a total dose of 25 Gray Equivalents (GyE) (Group 4). Participants were monitored for potential Dose Limiting Toxicities (DLT) for three weeks after the start of radiation. DLTs included:
Any grade 3 non-hematologic or hematologic toxicity requiring a greater than 7 day interruption in therapy (excluding alopecia and nausea/vomiting not controlled by optimal supportive care or
Any grade 4 non-hematologic toxicity or
Any grade 4 neutropenia or thrombocytopenia as defined by Common Terminology Criteria for Adverse Events (CTCAE v3.0)</description>
        <time_frame>3 Weeks</time_frame>
        <population>The participants treated with radiation therapy at the 5 fractions over 5 consecutive days</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Beam Radiation/ Capecitabine</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: 5 fractions over 5 consecutive days for a total of 25 Gray Equivalents (GyE)
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities in the 5 Radiation Sessions in One Week Arm</title>
          <description>The number of participants that experienced a dose limiting toxicity in the arm where radiation was administered over 5 consecutive for a total dose of 25 Gray Equivalents (GyE) (Group 4). Participants were monitored for potential Dose Limiting Toxicities (DLT) for three weeks after the start of radiation. DLTs included:
Any grade 3 non-hematologic or hematologic toxicity requiring a greater than 7 day interruption in therapy (excluding alopecia and nausea/vomiting not controlled by optimal supportive care or
Any grade 4 non-hematologic toxicity or
Any grade 4 neutropenia or thrombocytopenia as defined by Common Terminology Criteria for Adverse Events (CTCAE v3.0)</description>
          <population>The participants treated with radiation therapy at the 5 fractions over 5 consecutive days</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 or Greater Toxicity in Phase II</title>
        <description>Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3). The regimen was considered to be tolerated if less than 20% of participants experienced a grade 3 or greater toxicity.</description>
        <time_frame>30 days after the end of treatment, up to approximately 6 months total</time_frame>
        <population>Participants in the Phase II portion of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II: Proton Beam Radiation/ Capecitabine</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: 5 fractions over 5 consecutive days for a total of 25 Gray Equivalents (GyE)
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Greater Toxicity in Phase II</title>
          <description>Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3). The regimen was considered to be tolerated if less than 20% of participants experienced a grade 3 or greater toxicity.</description>
          <population>Participants in the Phase II portion of the trial</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Pathological Complete Response</title>
        <description>All patients that received surgery underwent a full pathological review of their pancreaticoduodenectomy specimen according to the American Joint Committee on Cancer (AJCC) Staging Classification, 6th. Initial gross evaluation and identification of resection margins was performed jointly by the surgeon and the pathologist. Pathological complete response will be defined as the absence of any viable tumor cells within the pathologic specimen.</description>
        <time_frame>at the time of surgery (28-42 days after start of treatment)</time_frame>
        <population>The eligible participants who underwent surgical resection. The phase I arms and Phase II group were combined together for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Beam Radiation/ Capecitabine</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: Given over different schedules and duration
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Pathological Complete Response</title>
          <description>All patients that received surgery underwent a full pathological review of their pancreaticoduodenectomy specimen according to the American Joint Committee on Cancer (AJCC) Staging Classification, 6th. Initial gross evaluation and identification of resection margins was performed jointly by the surgeon and the pathologist. Pathological complete response will be defined as the absence of any viable tumor cells within the pathologic specimen.</description>
          <population>The eligible participants who underwent surgical resection. The phase I arms and Phase II group were combined together for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression Free Survival</title>
        <description>The median amount of time from the start of treatment until death or disease progression, whichever occurs first.
Progressive Disease (PD): A 20% or greater increase in the sum of Longest Diameter (LD) of all target lesions, taking as reference the smallest sum LD recorded since baseline.</description>
        <time_frame>from the start of treatment until death or progression, median duration of 10.4 months</time_frame>
        <population>Two participants were excluded from the analysis because of ineligible final diagnoses (cholangiocarcinoma and autoimmune pancreatitis)</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Beam Radiation/ Capecitabine</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: Given over different schedules and duration
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival</title>
          <description>The median amount of time from the start of treatment until death or disease progression, whichever occurs first.
Progressive Disease (PD): A 20% or greater increase in the sum of Longest Diameter (LD) of all target lesions, taking as reference the smallest sum LD recorded since baseline.</description>
          <population>Two participants were excluded from the analysis because of ineligible final diagnoses (cholangiocarcinoma and autoimmune pancreatitis)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7.5" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Morbidity</title>
        <description>Number of participants with pancreatic or any other anastomotic leakage within 30 days of surgery</description>
        <time_frame>30 days post surgery (surgery was 28-42 days after the start of treatment)</time_frame>
        <population>The eligible participants who underwent surgical resections. The phase I arms and Phase II group were combined together for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Beam Radiation/ Capecitabine</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: Given over different schedules and duration
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Morbidity</title>
          <description>Number of participants with pancreatic or any other anastomotic leakage within 30 days of surgery</description>
          <population>The eligible participants who underwent surgical resections. The phase I arms and Phase II group were combined together for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-Day Post Operative Mortality</title>
        <description>The number of participants that died within 30 days of undergoing a pancreaticoduodenectomy.</description>
        <time_frame>30 days after the time of surgery (Surgery is 28-42 days after start of treatment)</time_frame>
        <population>The eligible participants who underwent surgical resection. The phase I arms and Phase II group were combined together for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Beam Radiation/ Capecitabine</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: Given over different schedules and duration
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>30-Day Post Operative Mortality</title>
          <description>The number of participants that died within 30 days of undergoing a pancreaticoduodenectomy.</description>
          <population>The eligible participants who underwent surgical resection. The phase I arms and Phase II group were combined together for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Related Serious Adverse Events</title>
        <description>The number of participants that had treatment related serious adverse events. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3). Adverse events were considered to be serious adverse events if they were grade 3 or greater and were considered to be possibly, probably, or definitely related to treatment.</description>
        <time_frame>From the start of treatment until 30 days after the end of treatment, up to approximately 5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Beam Radiation/ Capecitabine Dose Level 1</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: Given over 10 Radiation Sessions over 2 weeks
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Proton Beam Radiation/ Capecitabine Dose Level 2</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation sessions: 3 in week 1 and 2 in week 2
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Proton Beam Radiation/ Capecitabine Dose Level 3</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation sessions: 4 in week 1 and 1 in week 2
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Proton Beam Radiation/ Capecitabine Dose Level 4</title>
            <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation Sessions in one week
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Related Serious Adverse Events</title>
          <description>The number of participants that had treatment related serious adverse events. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3). Adverse events were considered to be serious adverse events if they were grade 3 or greater and were considered to be possibly, probably, or definitely related to treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of treatment until 30 days after the end of treatment, up to approximately approximately 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Proton Beam Radiation/ Capecitabine Dose Level 1</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over 10 Radiation Sessions over 2 weeks
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Proton Beam Radiation/ Capecitabine Dose Level 2</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation sessions: 3 in week 1 and 2 in week 2
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Proton Beam Radiation/ Capecitabine Dose Level 3</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation sessions: 4 in week 1 and 1 in week 2
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
        <group group_id="E4">
          <title>Proton Beam Radiation/ Capecitabine Dose Level 4</title>
          <description>Procedure/Surgery:
Proton Beam Radiation: Given over 5 Radiation Sessions in one week
Drug:
Capecitabine: Given orally starting on day one of radiation therapy for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Chest Wall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="23" subjects_affected="15" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="43" subjects_affected="29" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="33" subjects_affected="21" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT- SGPT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>AST- SGOT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="20" subjects_affected="10" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abdomen- pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Back- pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Extremity-limb- pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore Hong, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-1159</phone>
      <email>TSHONG1@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

